Adrenoleukodystrophy: Survey of 303 cases: Biochemistry, diagnosis, and therapy

H. W. Moser, Ann B. Moser, I. Singh, B. P. O'Neill

Research output: Contribution to journalArticle

Abstract

Adrenoleukodystrophy (ALD) is a genetically determined disorder associated with progressive central demyelination and adrenal cortical insufficiency. All affected persons show increased levels of saturated unbranched very-long-chain fatty acids, particularly hexacosanoate (C26:0), because of impaired capacity to degrade these acids. This degradation normally takes place in a subcellular organelle called the peroxisome, and ALD, together with Zellweger's cerebrohepatorenal syndrome, is now considered to belong to the newly formed category of peroxisomal disorders. Biochemical assays permit prenatal diagnosis, as well as identification of most heterozygotes. We have identified 303 patients with ALD in 217 kindreds. These patients show a wide phenotypic variation. Sixty percent of patients had childhood ALD and 17% adrenomyeloneuropathy, both of which are X-linked, with the gene mapped to Xq28. Neonatal ALD, a distinct entity with autosomal recessive inheritance and points of resemblance to Zellweger's syndrome, accounted for 7% of the cases. Although excess C26:0 in the brain of patients with ALD is partially of dietary origin, dietary C26:0 restriction did not produce clear benefit. Bone marrow transplant lowered the plasma C26:0 level but failed to arrest neurological progression.

Original languageEnglish (US)
Pages (from-to)628-641
Number of pages14
JournalAnnals of Neurology
Volume16
Issue number6
StatePublished - 1984

Fingerprint

Adrenoleukodystrophy
Biochemistry
Zellweger Syndrome
Peroxisomal Disorders
Therapeutics
Adrenal Insufficiency
X-Linked Genes
Peroxisomes
Demyelinating Diseases
Heterozygote
Prenatal Diagnosis
Organelles
Surveys and Questionnaires
Fatty Acids
Bone Marrow
Transplants
Acids
Brain

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Adrenoleukodystrophy : Survey of 303 cases: Biochemistry, diagnosis, and therapy. / Moser, H. W.; Moser, Ann B.; Singh, I.; O'Neill, B. P.

In: Annals of Neurology, Vol. 16, No. 6, 1984, p. 628-641.

Research output: Contribution to journalArticle

Moser, HW, Moser, AB, Singh, I & O'Neill, BP 1984, 'Adrenoleukodystrophy: Survey of 303 cases: Biochemistry, diagnosis, and therapy', Annals of Neurology, vol. 16, no. 6, pp. 628-641.
Moser, H. W. ; Moser, Ann B. ; Singh, I. ; O'Neill, B. P. / Adrenoleukodystrophy : Survey of 303 cases: Biochemistry, diagnosis, and therapy. In: Annals of Neurology. 1984 ; Vol. 16, No. 6. pp. 628-641.
@article{03c0b313e79542cc93288757e4b5de12,
title = "Adrenoleukodystrophy: Survey of 303 cases: Biochemistry, diagnosis, and therapy",
abstract = "Adrenoleukodystrophy (ALD) is a genetically determined disorder associated with progressive central demyelination and adrenal cortical insufficiency. All affected persons show increased levels of saturated unbranched very-long-chain fatty acids, particularly hexacosanoate (C26:0), because of impaired capacity to degrade these acids. This degradation normally takes place in a subcellular organelle called the peroxisome, and ALD, together with Zellweger's cerebrohepatorenal syndrome, is now considered to belong to the newly formed category of peroxisomal disorders. Biochemical assays permit prenatal diagnosis, as well as identification of most heterozygotes. We have identified 303 patients with ALD in 217 kindreds. These patients show a wide phenotypic variation. Sixty percent of patients had childhood ALD and 17{\%} adrenomyeloneuropathy, both of which are X-linked, with the gene mapped to Xq28. Neonatal ALD, a distinct entity with autosomal recessive inheritance and points of resemblance to Zellweger's syndrome, accounted for 7{\%} of the cases. Although excess C26:0 in the brain of patients with ALD is partially of dietary origin, dietary C26:0 restriction did not produce clear benefit. Bone marrow transplant lowered the plasma C26:0 level but failed to arrest neurological progression.",
author = "Moser, {H. W.} and Moser, {Ann B.} and I. Singh and O'Neill, {B. P.}",
year = "1984",
language = "English (US)",
volume = "16",
pages = "628--641",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Adrenoleukodystrophy

T2 - Survey of 303 cases: Biochemistry, diagnosis, and therapy

AU - Moser, H. W.

AU - Moser, Ann B.

AU - Singh, I.

AU - O'Neill, B. P.

PY - 1984

Y1 - 1984

N2 - Adrenoleukodystrophy (ALD) is a genetically determined disorder associated with progressive central demyelination and adrenal cortical insufficiency. All affected persons show increased levels of saturated unbranched very-long-chain fatty acids, particularly hexacosanoate (C26:0), because of impaired capacity to degrade these acids. This degradation normally takes place in a subcellular organelle called the peroxisome, and ALD, together with Zellweger's cerebrohepatorenal syndrome, is now considered to belong to the newly formed category of peroxisomal disorders. Biochemical assays permit prenatal diagnosis, as well as identification of most heterozygotes. We have identified 303 patients with ALD in 217 kindreds. These patients show a wide phenotypic variation. Sixty percent of patients had childhood ALD and 17% adrenomyeloneuropathy, both of which are X-linked, with the gene mapped to Xq28. Neonatal ALD, a distinct entity with autosomal recessive inheritance and points of resemblance to Zellweger's syndrome, accounted for 7% of the cases. Although excess C26:0 in the brain of patients with ALD is partially of dietary origin, dietary C26:0 restriction did not produce clear benefit. Bone marrow transplant lowered the plasma C26:0 level but failed to arrest neurological progression.

AB - Adrenoleukodystrophy (ALD) is a genetically determined disorder associated with progressive central demyelination and adrenal cortical insufficiency. All affected persons show increased levels of saturated unbranched very-long-chain fatty acids, particularly hexacosanoate (C26:0), because of impaired capacity to degrade these acids. This degradation normally takes place in a subcellular organelle called the peroxisome, and ALD, together with Zellweger's cerebrohepatorenal syndrome, is now considered to belong to the newly formed category of peroxisomal disorders. Biochemical assays permit prenatal diagnosis, as well as identification of most heterozygotes. We have identified 303 patients with ALD in 217 kindreds. These patients show a wide phenotypic variation. Sixty percent of patients had childhood ALD and 17% adrenomyeloneuropathy, both of which are X-linked, with the gene mapped to Xq28. Neonatal ALD, a distinct entity with autosomal recessive inheritance and points of resemblance to Zellweger's syndrome, accounted for 7% of the cases. Although excess C26:0 in the brain of patients with ALD is partially of dietary origin, dietary C26:0 restriction did not produce clear benefit. Bone marrow transplant lowered the plasma C26:0 level but failed to arrest neurological progression.

UR - http://www.scopus.com/inward/record.url?scp=0021712568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021712568&partnerID=8YFLogxK

M3 - Article

C2 - 6524872

AN - SCOPUS:0021712568

VL - 16

SP - 628

EP - 641

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -